Vicapsys Life Sciences, Inc.

2024 Q3 Form 10-K Financial Statement

#000149315224041809 Filed on October 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2023 Q4 2023

Balance Sheet

Concept 2024 Q3 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $9.422K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $30.23K
Receivables
Other Receivables
Total Short-Term Assets $39.66K
YoY Change -44.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $39.66K
Total Long-Term Assets $0.00
Total Assets $39.66K
YoY Change -44.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $537.4K
YoY Change -15.39%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $18.71K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.968M
YoY Change 92.44%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.968M
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$16.30M
YoY Change 7.82%
Common Stock $32.07K
YoY Change 2.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$1.929M
YoY Change
Total Liabilities & Shareholders Equity $39.66K
YoY Change -44.94%

Cashflow Statement

Concept 2024 Q3 2023 Q4 2023

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001468639
CY2023Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
usd
CY2023Q4 VICP Common Stock To Be Issued
CommonStockToBeIssued
usd
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
usd
CY2022 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2022 VICP Financing Costs
FinancingCosts
usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
usd
CY2022 VICP Stock Issued During Period Value Issuance For Common Stock To Be Issued
StockIssuedDuringPeriodValueIssuanceForCommonStockToBeIssued
usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings
AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings
usd
CY2023 VICP Stock Issued During Period Value Issuance For Common Stock To Be Issued
StockIssuedDuringPeriodValueIssuanceForCommonStockToBeIssued
usd
CY2023 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
usd
CY2023 VICP Stock Issued During Period Value Common Stock To Be Issued Pursuant To Private Placement One
StockIssuedDuringPeriodValueCommonStockToBeIssuedPursuantToPrivatePlacementOne
usd
CY2023 us-gaap Adjustment For Amortization
AdjustmentForAmortization
usd
CY2023 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2022 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
usd
CY2022 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
usd
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CY2022 us-gaap Stock Issued1
StockIssued1
usd
CY2023 VICP Deferred Offering Costs In Accounts Payable
DeferredOfferingCostsInAccountsPayable
usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
CY2022Q4 VICP Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
shares
CY2022Q4 VICP Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Public Float
EntityPublicFloat
4658159 usd
CY2023 dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32071299 shares
CY2023 VICP No Insider Trading Flag
NoInsiderTradingFlag
true
CY2023 dei Auditor Firm
AuditorFirmId
4048
CY2023 dei Auditor Name
AuditorName
Assurance Dimensions
CY2023 dei Auditor Location
AuditorLocation
Coral Springs, Florida
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9422 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14097 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
30234 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
7483 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
50441 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
39656 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
72021 usd
CY2023Q4 us-gaap Assets
Assets
39656 usd
CY2022Q4 us-gaap Assets
Assets
72021 usd
CY2023Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
961708 usd
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
635183 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
537449 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
272317 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
115312 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
115312 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
18712 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
335156 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1968337 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1022812 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32071299 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32071299 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31188460 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31188460 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
32071 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
31188 usd
CY2023Q4 VICP Common Stock To Be Issued Par Or Stated Value Per Share
CommonStockToBeIssuedParOrStatedValuePerShare
0.001
CY2022Q4 VICP Common Stock To Be Issued Par Or Stated Value Per Share
CommonStockToBeIssuedParOrStatedValuePerShare
0.001
CY2023Q4 VICP Common Stock To Be Issued Shares Outstanding
CommonStockToBeIssuedSharesOutstanding
0 shares
CY2022Q4 VICP Common Stock To Be Issued Shares Outstanding
CommonStockToBeIssuedSharesOutstanding
727281 shares
CY2022Q4 VICP Common Stock To Be Issued
CommonStockToBeIssued
727 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14339323 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
14135257 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16300075 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15117963 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1928681 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-950791 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39656 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72021 usd
CY2023 VICP Personnel Costs
PersonnelCosts
262625 usd
CY2022 VICP Personnel Costs
PersonnelCosts
122458 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15267 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13097 usd
CY2023 us-gaap Professional Fees
ProfessionalFees
672655 usd
CY2022 us-gaap Professional Fees
ProfessionalFees
448806 usd
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
340231 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
96431 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60198 usd
CY2023 us-gaap Operating Expenses
OperatingExpenses
1046978 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
984790 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-1046978 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-984790 usd
CY2023 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
19969 usd
CY2023 VICP Financing Costs
FinancingCosts
115165 usd
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-135134 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1182112 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1182112 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-984790 usd
CY2022 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
3548 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34548676 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34548676 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30577988 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30577988 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-121651 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
50000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
105650 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-984790 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-950791 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-950791 usd
CY2023 VICP Stock Issued During Period Value Common Stock To Be Issued Pursuant To Private Placement
StockIssuedDuringPeriodValueCommonStockToBeIssuedPursuantToPrivatePlacement
100000 usd
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
83526 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20697 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1182112 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1928681 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-1928681 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1182112 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-984790 usd
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
31289 usd
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
340231 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
20697 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
105650 usd
CY2023 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
115082 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-37152 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1985 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
326525 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
111951 usd
CY2023 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
265132 usd
CY2022 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
159457 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-417524 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-238197 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50000 usd
CY2023 VICP Proceeds From Deferred Offering Costs
ProceedsFromDeferredOfferingCosts
50441 usd
CY2022 VICP Proceeds From Deferred Offering Costs
ProceedsFromDeferredOfferingCosts
-15001 usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000 usd
CY2023 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
-41192 usd
CY2023 us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
303600 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
412849 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34999 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4675 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-203198 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14097 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
217295 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9422 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14097 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
19969 usd
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
545 usd
CY2023 us-gaap Stock Issued1
StockIssued1
83526 usd
CY2022 VICP Deferred Offering Costs In Accounts Payable
DeferredOfferingCostsInAccountsPayable
35440 usd
CY2017Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
effected a 1-for-100 reverse stock split of its outstanding common stock
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-1182112 usd
CY2023Q4 VICP Working Capital Deficit
WorkingCapitalDeficit
1928682 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-16300075 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
50000 usd
CY2023Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
0 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13097 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3397281 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2780682 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3397281 shares
CY2023 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
31289 usd
CY2022 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
340231 usd
CY2022Q2 VICP Nonrefundable Annual License Fee
NonrefundableAnnualLicenseFee
10000 usd
CY2022Q1 us-gaap Royalty Expense
RoyaltyExpense
100000 usd
CY2023Q4 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
83526 usd
CY2023 us-gaap Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
328571 shares
CY2023Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2024-01-27
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
363000 usd
CY2023Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
363000 usd
CY2023Q4 VICP Debt Instrument Annual Principal Payment Debt Modification Debt Discount
DebtInstrumentAnnualPrincipalPaymentDebtModificationDebtDiscount
33000 usd
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
5156 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
335156 usd
CY2022Q2 VICP Nonrefundable Annual License Fee
NonrefundableAnnualLicenseFee
10000 usd
CY2023Q4 VICP Nonrefundable Annual Royalty
NonrefundableAnnualRoyalty
100000 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7440000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7440000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32071299 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31188460 shares
CY2023Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
400000 shares
CY2023Q2 us-gaap Stock Issued1
StockIssued1
83526 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
50000 usd
CY2022Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
100000 shares
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.50
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
54267 shares
CY2022Q3 VICP Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Capital Raise
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsCapitalRaise
0.25
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0293 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.95 pure
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1900000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.66
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M29D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
770000 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.50
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2670000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.62
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M15D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2670000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.62
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M15D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2670000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.62
CY2023 VICP Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P5Y2M15D
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
3548 usd
CY2021Q4 VICP Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingAndExercisableNumber
4060000 shares
CY2021Q4 VICP Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableWeightedAverageExercisePrice
0.53
CY2022 VICP Share Based Compensation Arrangement By Share Based Payment Award Weightedaverage Remaining Life Year Outstanding And Exercisable
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedaverageRemainingLifeYearOutstandingAndExercisable
P1Y6M
CY2022 VICP Stock Issued During Period Shares Stock Options Stock Issued During Period Shares Stock Options Expired
StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExpired
3960000 shares
CY2022 VICP Share Based Compensation Arrangements By Share Based Payment Award Nono Otions Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonoOtionsExpirationsInPeriodWeightedAverageExercisePrice
0.51
CY2022 VICP Stock Issued During Period Shares Stock Options Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsStockIssuedDuringPeriodSharesStockOptionsExercised
100000 shares
CY2022 VICP Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
0.50
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
13953510 usd
CY2023 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
2033 to 2039
CY2023Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
2930237 usd
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1182112 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
984790 usd
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-248244 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-206806 usd
CY2023 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
4346 usd
CY2022 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
22187 usd
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
243898 usd
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
184620 usd
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2985572 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2741675 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2985572 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2741675 usd

Files In Submission

Name View Source Status
0001493152-24-041809-index-headers.html Edgar Link pending
0001493152-24-041809-index.html Edgar Link pending
0001493152-24-041809.txt Edgar Link pending
0001493152-24-041809-xbrl.zip Edgar Link pending
audit_001.jpg Edgar Link pending
audit_002.jpg Edgar Link pending
audit_003.jpg Edgar Link pending
audit_004.jpg Edgar Link pending
audit_005.jpg Edgar Link pending
ex21-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vicp-20231231.xsd Edgar Link pending
vicp-20231231_def.xml Edgar Link unprocessable
vicp-20231231_pre.xml Edgar Link unprocessable
vicp-20231231_lab.xml Edgar Link unprocessable
vicp-20231231_cal.xml Edgar Link unprocessable